In breast cancer cells, the use of an MEK inhibitor (trametinib) in combination with rosiglitazone for adipogenic transdifferentiation therapy strongly promoted the direct lineage differentiation of these cancer cells. This evidence concerns the gene MAP2K7 and breast carcinoma.